Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
09 3월 2023 - 8:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of March, 2023
(Commission File No. 001-41157)
BIONOMICS LIMITED
(Translation of registrant’s name into English)
200 Greenhill Road
Eastwood SA 5063
Tel: +618 8150 7400
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☐
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On March 9, 2023, Bionomics Limited (the “Company”) lodged a press release with the Australian Securities Exchange (the “ASX”), announcing an update to the analysis from the PREVAIL Phase 2 Study of BNC210. The press release is furnished herewith as Exhibit 99.1 to this report on Form 6-K.
1
EXHIBIT INDEX
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
|
|
|
Bionomics Limited |
|
(Registrant) |
|
|
|
|
By: |
/s/ Errol De Souza |
|
Name: |
Errol De Souza, Ph.D. |
|
Title: |
Non-Executive Chairman |
Date: March 9, 2023
3
Bionomics (NASDAQ:BNOX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Bionomics (NASDAQ:BNOX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024